Gilead Sciences (NASDAQ:GILD) Stock Rating Lowered by Wall Street Zen

Gilead Sciences (NASDAQ:GILD) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

GILD has been the subject of several other research reports. Daiwa Securities Group dropped their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Zacks Research raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $150.99 on Friday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average price of $136.67 and a 200-day moving average price of $136.39. The company has a market cap of $187.22 billion, a price-to-earnings ratio of -56.55 and a beta of 0.33. Gilead Sciences has a 12 month low of $108.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. During the same period last year, the firm earned $2.01 earnings per share. Gilead Sciences’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, equities analysts anticipate that Gilead Sciences will post -0.48 EPS for the current year.

Insider Buying and Selling

In other news, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total value of $415,080.00. Following the sale, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock worth $14,495,820 over the last quarter. Company insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GILD. Brighton Jones LLC lifted its holdings in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $215,000. Sivia Capital Partners LLC increased its position in Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares in the last quarter. Ieq Capital LLC raised its stake in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC boosted its holdings in Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 674 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV and oncology approvals broaden Gilead’s growth prospects. FDA approval of Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults on complex treatments, could strengthen the company’s HIV franchise. Separately, European approval of Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients expands Gilead’s oncology opportunity. Commercial uptake will determine the ultimate revenue impact. HIV and oncology approvals article
• Positive Sentiment: Analysts raised long-term earnings expectations. Zacks Research increased its Q1 2028 EPS estimate to $2.15, Q2 2028 to $2.31 and FY2028 to $9.66, while maintaining a “Strong Buy” rating. The revisions suggest improving confidence in Gilead’s future profitability. Gilead analyst estimates
• Positive Sentiment: An Arcus-backed cancer study reached completion. The milestone sets up a potentially important immuno-oncology catalyst, although investors will likely need to wait for efficacy and safety data before assigning significant value to the program. Arcus-backed cancer trial article
• Neutral Sentiment: Gilead continues to support income investors with a $0.82 quarterly dividend. The $3.28 annualized payout provides shareholder support, but the high payout relative to reported earnings makes future dividend growth dependent on sustained HIV cash flow and successful new-product launches. Gilead dividend article
• Neutral Sentiment: CEO Daniel O’Day sold $2.23 million of stock. The 15,000-share sale reduced his holdings by 2.53%, but it was completed under a pre-arranged Rule 10b5-1 plan, limiting its value as a bearish signal. SEC insider trading filing
• Negative Sentiment: Investors remain concerned about concentration and patent-expiration risk. Gilead’s dividend and cash generation depend heavily on its leading HIV franchise, particularly a blockbuster therapy facing a known patent expiration later in the next decade. The sharp decline in cell-therapy licensing deals also highlights uncertainty around diversification beyond HIV. Gilead dividend and patent risk article

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.